MedPath

The efficacy of complementory use of memantine in treatment of schizophrenia with chronic course

Phase 2
Conditions
Schizophrenia.
Schizophrenia
Registration Number
IRCT201306015605N1
Lead Sponsor
Clinical psychiatry research center, Tabriz university of medical sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Exclusion criteria:
Substance abuse; IQ of less than 70; Medical history of other mental disorder; Other clinical and neurological disorders; Taking antipsychotic medications during last week or long acting antipsychotic medications during past month; Receiving ECT in the past two weeks; Sensitivity to Memantine

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Schizophrenia severity. Timepoint: 6 monthes. Method of measurement: Clinical assesment.
Secondary Outcome Measures
NameTimeMethod
Side effects. Timepoint: Two month after begining of the study. Method of measurement: Clinical assessment.
© Copyright 2025. All Rights Reserved by MedPath